Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
08 2022
Historique:
revised: 13 02 2022
received: 21 09 2021
accepted: 14 03 2022
pubmed: 1 5 2022
medline: 20 7 2022
entrez: 30 4 2022
Statut: ppublish

Résumé

To describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction, yet some HCM patients develop impaired systolic function that is associated with worse outcomes. Our registry included 1328 HCM patients from two centres in Spain and Israel. Patients with normal baseline ventricular function were matched, and a competing-risk analysis was performed to find factors associated with HCMr development. Patient records were reviewed to recognize clinically significant events that occurred closely before the development of HCMr. Genetic data were collected in patients with HCMr. A composite of all-cause mortality or ventricular assist device (VAD)/heart transplantation was assessed according to ventricular function. Median age was 56, and 34% were female patients. HCMr at evaluation was seen in 37 (2.8%) patients, and 46 (3.5%) developed HCMr during median follow up of 9 years. HCMr was associated with younger age of diagnosis, poor functional class, and ventricular arrhythmia. Atrial fibrillation, pacemaker implantation, and baseline left ventricular ejection fraction (LVEF) of ≤55% were significant predictors of future HCMr development, while LV obstruction predicted a lower risk. Genetic testing performed in 53 HCMr patients, identifying one or more pathogenic variant in 38 (72%): most commonly in myosin binding protein C (n = 20). Six of these patients had an additional pathogenic variant in one of the sarcomere genes. Patients with baseline HCMr had a higher risk (hazard ratio 6.4, 4.1-10.1) for the composite outcome and for the individual components. Patients who developed HCMr in the course of the study had similar mortality but a higher rate of VAD/heart transplantation compared with HCM with normal LVEF. Hypertrophic cardiomyopathy with reduced ejection fraction is associated with heart failure and poor outcome. Arrhythmia, cardiac surgery, and device implantation were commonly documented prior to HCMr development, suggesting they may be either a trigger or the result of adverse remodelling. Future studies should focus on prediction and prevention of HCMr.

Identifiants

pubmed: 35488723
doi: 10.1002/ehf2.13914
pmc: PMC9288812
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2301-2312

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

J Am Coll Cardiol. 2006 Mar 7;47(5):1043-8
pubmed: 16516091
Eur Heart J Qual Care Clin Outcomes. 2019 Oct 1;5(4):321-333
pubmed: 30715300
J Am Coll Cardiol. 2004 Dec 21;44(12):2329-32
pubmed: 15607394
Circulation. 2006 Jul 18;114(3):216-25
pubmed: 16831987
Heart Fail Rev. 2021 Sep;26(5):1023-1036
pubmed: 32040801
Heart. 2013 Dec;99(24):1800-11
pubmed: 23674365
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur J Heart Fail. 2014 Sep;16(9):950-7
pubmed: 25132132
Am J Cardiol. 2010 Jul 15;106(2):261-7
pubmed: 20599013
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Europace. 2007 Jan;9(1):50-4
pubmed: 17224423
J Card Fail. 2012 May;18(5):396-403
pubmed: 22555271
Eur Heart J. 2019 Jun 1;40(21):1671-1677
pubmed: 30358878
Circulation. 2003 May 6;107(17):2227-32
pubmed: 12707239
Eur Heart J. 2010 Sep;31(17):2111-23
pubmed: 20513729
ESC Heart Fail. 2022 Aug;9(4):2301-2312
pubmed: 35488723
Circulation. 2020 Apr 28;141(17):1371-1383
pubmed: 32228044
J Cardiovasc Electrophysiol. 2021 Jul;32(7):1961-1968
pubmed: 33825250
Eur J Heart Fail. 2019 Oct;21(10):1169-1186
pubmed: 31129923
Circ Genom Precis Med. 2020 Dec;13(6):e003117
pubmed: 33151750
Int J Cardiovasc Imaging. 2018 Apr;34(4):597-605
pubmed: 29071521
J Am Coll Cardiol. 2020 Jul 14;76(2):186-197
pubmed: 32646569
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972
Am Heart J. 2020 Jan;219:58-69
pubmed: 31726421
Curr Cardiol Rep. 2000 Mar;2(2):134-40
pubmed: 10980884
J Am Coll Cardiol. 2015 May 12;65(18):1915-28
pubmed: 25953744
Circ Res. 1998 Sep 21;83(6):580-93
pubmed: 9742053
J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345
pubmed: 31699273
Heart. 2015 Jul;101(13):1047-53
pubmed: 25935763
J Am Coll Cardiol. 2020 Jun 23;75(24):3033-3043
pubmed: 32553256
J Am Coll Cardiol. 2005 Oct 18;46(8):1543-50
pubmed: 16226182

Auteurs

Yishay Wasserstrum (Y)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

José M Larrañaga-Moreira (JM)

Unidad de Cardiopatías Familiares, Cardiology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.

Cristina Martinez-Veira (C)

Unidad de Cardiopatías Familiares, Cardiology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.

Edward Itelman (E)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Dor Lotan (D)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Avi Sabbag (A)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Rafael Kuperstein (R)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Yael Peled (Y)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Dov Freimark (D)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Roberto Barriales-Villa (R)

Unidad de Cardiopatías Familiares, Cardiology Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
Centro de Investigación Biomédica en Red (CIBERCV), Madrid, Spain.

Michael Arad (M)

Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.
Sackler School of Medicine, Tel-Aviv University, 35 Kalachkin St., Tel-Aviv, 6997801, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH